Neuropathology and Applied Neurobiology 44, 628-638 Altered expression of glutamate transporter-1 and water channel protein aquaporin-4 in human temporal cortex with Alzheimer's disease Aims: Glutamate neurotoxicity plays an important role in the pathogenesis of various neurodegenerative disorders. Many studies have demonstrated that glutamate transporter-1 (GLT-1), the dominant astrocytic glutamate transporter, is significantly reduced in the cerebral cortex of patients with Alzheimer's disease (AD), suggesting that glutamate-mediated excitotoxicity might contribute to the pathogenesis of AD. In a previous study, we have demonstrated marked alterations in the expression of the astrocytic water channel protein aquaporin-4 (AQP4) in relation to amyloid b deposition in human AD brains. As a functional complex, GLT-1 and AQP4 in astrocytes may play a neuroprotective role in the progression of AD pathology. However, few studies have examined the correlation between the expression of GLT-1 and that of AQP4 in human AD brain. Methods: Here, using immunohistochemistry with antibodies against GLT-1 and AQP4, we studied the expression levels and distribution patterns of GLT-1 in areas showing various patterns of AQP4 expression in autopsied temporal lobes from eight patients with AD and five controls without neurological disorders. Results: GLT-1 staining in the control group was present throughout the neocortex as uniform neuropil staining with co-localized AQP4. The AD group showed a significant reduction in GLT-1 expression, whereas cortical AQP4 immunoreactivity was more intense in the AD group than in the control group. There were two different patterns of GLT-1 and AQP4 expression in the AD group: (i) uneven GLT-1 expression in the neuropil where diffuse but intense AQP4 expression was evident, and (ii) senile plaque-like co-expression of GLT-1 and AQP4. Conclusions: These findings suggest disruption of glutamate/water homoeostasis in the AD brain.
Introduction
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by b-amyloid (Ab) plaques and neurofibrillary tangles, usually associated with cerebral amyloid angiopathy [1] . It is becoming increasingly recognized that an imbalance of Ab clearance underlies the pathogenesis of AD [2, 3] . However, the cellular and molecular mechanisms responsible for impairment of Ab clearance remain unclear. Recently, the paravascular drainage pathway, otherwise known as the glymphatic system, has been characterized [4] . In this pathway, the astroglial water channel aquaporin 4 (AQP4) is an important component, being highly expressed in perivascular astrocytic end-feet processes, and may play an important role in Ab clearance [5, 6] . Indeed, it has been shown that AQP4 deficiency in APP/PS1 mice leads to increased accumulation of brain Ab without any change in the levels of expression of proteins associated with Ab formation and degradation [7] . We have previously reported marked changes in the expression of astrocytic AQP4 in relation to Ab deposition in human AD brains [8] . These findings suggest that the process of Ab deposition might alter the astrocytic expression of AQP4 and thereby impair glymphatic clearance of Ab, thus creating a vicious cycle that drives amyloid aggregation in the AD brain.
On the other hand, many studies have shown that glutamate transporter-1 (GLT-1), the dominant astrocytic glutamate transporter in the cerebral cortex, is significantly reduced in the brains of AD patients [9] [10] [11] . Reduced glutamate uptake by the glutamate transporter can lead to increased extracellular levels of glutamate, triggering excessive stimulation of glutamate receptors, and resulting in synapse dysfunction, thus possibly contributing to AD pathogenesis [12, 13] . Furthermore, stimulation of the glutamate receptor can potentially increase Ab production during the course of AD [14] . Conversely, restoration of GLT-1 function may prevent excess glutamate-mediated neurotoxicity caused by Ab [15] , indicating that GLT-1 functions by limiting the neurotoxicity of prolonged glutamate exposure in AD.
A recent study has suggested that GLT-1 and AQP4 exist in astrocytic membranes as a macromolecular complex [16] . The preferential distribution of AQP4 in the perivascular domains of astrocytes and its co-localization with GLT-1 indicates that AQP4 may be involved in functional coupling between water and extracellular glutamate homoeostasis in the brain [17] . AQP4 deficiency in primary cultured astrocytes down-regulates glutamate uptake and GLT-1 expression [18] . Furthermore, reduction in GLT-1 expression in HEK-293 cells has shown to accompany AQP4 down-regulation after exposure to AQP4-specific autoantibodies [16] . Thus, AQP4 seems to play an important role in the function and expression of GLT-1, and regulation of the interaction between these two proteins may have a potentially neuroprotective effect against Ab-or glutamate-mediated neurotoxicity in the AD brain.
The existing data suggest that in order to fully understand the nature of AD, a full grasp of GLT-1-AQP4 biology is imperative. To the best of our knowledge, no previous studies have examined the relationship between the expression of GLT-1 and that of AQP4 in the human AD brain. In this study, therefore, we investigated the expression of GLT-1 in association with AQP4 in autopsied brains from AD patients. We also characterized a relevant and specific astrocytic enzyme, glutamine synthetase (GS), which converts glutamate to glutamine in astrocytes [19] [20] [21] , in relation to GLT-1 pathology in the AD brain.
Materials and methods
This study was approved by the Ethics Committee of Fukushima Medical University. Written informed consent for autopsy, collection of samples and subsequent use for research purposes was obtained from the next of kin of the deceased involved in the study. The brains of eight patients with AD and five control patients without neurological disorders were examined. The clinical data for these 13 patients have been published previously [8] and are summarized in the Table 1. All of the AD patients had a Braak NFT stage/amyloid deposit stage of VI/C [22] .
The diagnosis of AD was based on clinical history and post-mortem neuropathological verification [22] . The temporal lobes (superior, middle and inferior temporal gyri) of all individuals were used. Paraffinembedded sections 4 lm thick were immunostained using the methods described previously [8, 23] . The primary antibodies used were a rabbit polyclonal antibody against AQP4 (Santa Cruz; 1:500), a mouse monoclonal antibody against GLT-1 (Leica Biosystems, UK; 1:20), a mouse monoclonal antibody against glial fibrillary acidic protein (GFAP) (Chemicon, USA; 1:1000), a rabbit polyclonal antibody against GS (ATLAS, Sweden; 1:500) and a mouse monoclonal antibody against Ab42 (Millipore, USA; 1:300). GLT-1 immunoreactivity (IR) was semi-quantified using image analysis software (Win Roof; Mitani Corp., Tokyo, Japan), as described previously [8, 23] . Briefly, three random areas, each measuring 3.44 mm 2 , in the superior, middle and inferior temporal cortex were assessed. The quantification parameter employed was the relative density of the chromogen reaction, defined as the saturation value of GLT-1 immunostaining on digitized images. All data were expressed as means AE SD. One-way ANOVA, followed by the Bonferroni test, was performed for statistical comparisons of the GLT-1-IR levels measured semiquantitatively. Differences at P < 0.05 were considered statistically significant. A double-labelling immunofluorescence study was performed on paraffin sections to characterize the relationship between expression of AQP4 and that of GLT-1, or between expression of GLT-1 and that of GS. We used the anti-AQP4, anti-GLT-1 and GS antibodies mentioned above. As the secondary antibodies, we used Alexa Fluor 488 goat anti-mouse IgG (Life Technologies, USA; 1:200) and Cy3-conjugated donkey antirabbit IgG (Jackson, USA; 1:100). Images of immunolabelled preparations were captured with a microscope digital camera system (DP70; Olympus, Japan). Correlations between GLT-1 and AQP4 levels in terms of relative fluorescence units (RFU) were also assessed using both Spearman correlation and regression analyses. Five random areas, each measuring 0.14 mm 2 , in the superior, middle and inferior temporal gyri of the double-fluorescence-labelled (GLT-1 and AQP4) sections were assessed. Correlations between the levels of GLT-1 and AQP4 in terms of RFU were assessed using both Spearman correlation and regression analyses. The level of statistical significance was set at P < 0.05. For double peroxidase labelling of GLT-1 and GFAP, or GLT-1 and Ab42, we used the EnVision G|2 doublestain system (Dako, Denmark) in accordance with the manufacturer's protocol, employing the antibodies against GLT-1, GFAP and Ab42. Visualization was based on peroxidase using diaminobenzidine and alkaline phosphatase, with permanent red as the chromogen.
Results
In accordance with our previous study [8] , we noted that the expression of GLT-1 differed from that of AQP4. Single immunohistochemistry for GLT-1 or AQP4 revealed that GLT-1 and AQP4 immunostaining was detected diffusely in the grey matter, excluding the subpial layer in control brains (Figure 1a,d) . The pattern of the GLT-1 signal was denser and more diffuse than that of the AQP4 signal, despite the strong AQP4 immunoreaction in the subpial layer (Figure 1a,d ; note the arrows in the insets). In contrast, there was a profound loss of GLT-1 expression in the upper and lower cortical layers of AD brains (Figure 1e,f) , and enhanced expression of AQP4 was observed throughout the cortex, including the subpial area (Figure 1b,c ). There were two prominent patterns of cortical AQP4 and GLT-1 immunostaining in the AD group: intense diffuse AQP4 labelling of the entire neuropil (Figure 1b) , in contrast to a reduced patchy GLT-1 immunoreaction (Figure 1e,g) , and an Ab plaque-like distribution of AQP4 and GLT-1 (Figure 1c ,f,h; note the arrowheads in the insets and arrows). We have observed previously that numerous Ab42 or Ab40 plaques are co-localized with intense expression of Ab plaque-like AQP4 [8] . In addition, numerous Ab42 plaques were co-localized with GLT-1 plaque-like immunostaining (Supplementary Data S1). Occasionally, cells with an astrocyte-like morphology showing positivity for AQP4 and GLT-1 were observed in the AD group (Figure 1i ). These results of AQP4 immunostaining were consistent with our previous reports, indicating that the levels of cortical AQP4 IR in the AD group were significantly higher than those in the control group [8] . The levels of cortical GLT-1 IR in the AD group were significantly lower than those in the control group. GLT-1 IR in each case, expressed as the mean AE SD for the inferior, middle and superior temporal cortices, was 63.7 AE 9.6, 60.4 AE 10.3 and 64.0 AE 9.8 in the control group, and 45.4 AE 8.2, 43.4 AE 8.6 and 50.8 AE 10.0 in the AD group respectively (Figure 1j-l) .
In the control group, double immunofluorescence for GLT-1 and AQP4 showed that immunoreactivity for GLT-1 was present throughout the neocortex as uniform neuropil staining with co-localized AQP4 Intensity of the GLT-1 immunoreactivity (IR) in each temporal neocortex area in the AD group is significantly weaker than that in the control group. Data are given as mean AE SD. **P < 0.01 vs. Control.
( Figure 2a-c) . In some regions of control brains, however, neuropil staining of GLT-1/AQP4 was patchy. In AD cases, uniform or even staining for GLT-1/AQP4 was markedly decreased, in contrast to the control brains (Figure 2d-i) . There were two different patterns of GLT-1 and AQP4 expression in the AD group: (i) patchy loss of GLT-1 immunoreactivity in the neuropil, where diffuse intense AQP4 immunostaining was evident (AD-lesion type 1), and (ii) senile plaque (SP)-like co-expression of GLT-1 and AQP4 (AD-lesion type 2, note the inset). The semi-quantitatively determined levels of GLT-1 and AQP4 in RFU showed a significant positive correlation in AD type 2 lesions and in the overall AD lesion (AD type 1 lesions + type 2 lesions) area, but not in the AD type 1 lesion area (Figure 3 ).
When analysing perivascular regions for GLT-1 and AQP4 in both the control and AD groups, we noticed a variety of inconsistent patterns of GLT-1 and AQP4 expression (Figure 4a -l, note the asterisk and arrows). In control brains, perivascular co-localization of GLT-1 and AQP4 expression was observed frequently (Figure 4a-c) , whereas the co-localization in AD brains became less frequent because of profound GLT-1 loss (Figure 4d-i) . However, strong perivascular co-expression of GLT-1 and AQP4 was seen infrequently in the AD group (Figure 4j-l) . In addition, GLT-1-positive cells were co-localized with AQP4 immunoreactivity on some astrocyte processes in close proximity to vessels in the AD neocortex, but did not seem to be in contact with the vessel walls (Figure 4g- arrowheads). In the AD brain, perivascular AQP4 expression varied; Figure 4e ,h,k show a mild decrease, a profound decrease and strong expression of AQP4, respectively, as reported previously [8] . Double immunofluorescence staining for GLT-1 and GS showed that GS-positive cells in control brains had the characteristics of protoplasmic astrocytes with multiple elaborate processes extending from cell somata, and these GS-positive cells appeared to overlap with diffuse GLT-1 signals in the neuropil (Figure 5a-c) . On the other hand, reduced numbers of GS-immunoreactive astrocytes with fewer processes than those in control brains were observed in areas of profound GLT-1 reduction (Figure 5d-f) or around SPlike expression of GLT-1 (Figure 5g-i) . Occasional faint SP-like expression of GS was seen in AD brains (Figure 5h, arrows) , showing co-localization with intense SP-like GLT-1 expression. Immunohistochemical assessment of GFAP showed that AD cases had moderately or highly reactive astrocytosis with enhanced GFAP expression in the neocortex, whereas the control group showed slightly or mildly reactive astrocytosis (Supplementary Data S2). Double peroxidase labelling for GLT-1 (red) and GFAP (brown) demonstrated markedly reduced GLT-1 immunostaining and intense GFAP-positive astrocytosis in the AD neocortex relative to controls (Figure 5j-l) . Additionally, a SP-like co-expression pattern of GLT-1 and GFAP was also seen in the AD neocortex (Figure 5l , note the arrows), as reported previously by others [9] . In the negative control sections stained without primary antibodies, no or faint lipofuscin-like granular IR was observed.
Discussion
Utilizing two specific markers of astroglial function, we examined morphometrically the characteristic Figure 3 . Plots of GLT-1 and AQP4 IR levels (relative fluorescence units) in AD type 1 lesions, AD type 2 lesions and the total lesion (AD type 1 + type 2) area. Semiquantitative analysis revealed a significant positive correlation between GLT-1 and AQP4 in the AD type 2 lesion area (R 2 = 0.3003, P = 0.000037) or in the total area (R 2 = 0.1534, P = 0.0029), but not in the AD type 1 lesion area.
distribution of GLT-1 in relation to AQP4 in the cortex of the human AD brain. Two distinctly different distribution patterns were observed: AD type 1 lesions characterized by uneven GLT-1 expression in the neuropil along with diffuse but intense AQP4 expression, and AD type 2 lesions located in the vicinity of SPs, characterized by prominent co-expression of GLT-1 and AQP4. In addition, perivascular astrocytes in the AD neocortex expressed GLT-1 and AQP4 to various degrees. Although several reports have evaluated the pattern of GLT-1 or AQP4 expression in AD [8, 9, 24, 25] , none have investigated in detail the expression of GLT-1 in relation to that of AQP4 in the human AD brain. Co-expression of another glutamate transporter, GLAST, with AQP4 was discovered in the rat brain utilizing electron microscopy in the early 1990s [26] , and a few studies have reported that GLT-1 is co-localized with AQP4 in several neurological disorders [16, 27, 28] . Our present data for GLT-1/AQP4 in the AD brain reflect some facets of astrogliopathology in AD pathogenesis [29] . In general, astrocytes surrounding SPs show a reactive phenotype characterized by an increase in GFAP expression, while tau-associated lesions such as neuropil threads and tangles with neuronal and synaptic loss can cause a non-Ab plaque associated with astroglial reactions [30] . The pattern of GLT-1 and AQP4 expression in AD type 1 lesions seems to reflect astrogliosis in non-plaque areas with minimal amyloid deposits, whereas that in AD type 2 lesions reflects an astrocytic plaque-related reaction in areas of SPs. Furthermore, the mottled distribution of these immunoreactive molecules in AD type 1 lesions may represent an evolutionary stage of SP formation in AD type 2 lesions. From another viewpoint, the various degrees of GLT-1 and AQP4 expression we observed might be explained by a change in astrocyte polarity defined by mislocalization/redistribution of GLT-1 and AQP4 [31, 32] . What do the astrocytic components of SP represent in the context of AD pathogenesis? Ab plaques could contribute to local neural system destruction throughout the course of AD [33] . Activation of astrocytes surrounding Ab plaque is the hallmark of AD, but the factors triggering it, and its consequences, remain poorly understood. GFAP is one of the best indicator molecules for detection of SPs in AD [34] . APP/PS1 transgenic mice show increased immunoreactivity for connexin-43 (Cx43) and Cx30 in ring-like areas at the periphery of SPs [35] . It has been speculated that some factors in the microenvironment of SPs may alter the structural and functional properties of plaque-associated reactive astrocytes in AD, and that remodelling of Cxs in the peri-plaque area may contribute to AD pathology. In this study, increased immunoreactivity for AQP4 was detected in the majority of plaques, contributing to the overall increase in AQP4 expression in our AD cases, whereas despite enhanced GLT-1 expression in plaques, overall GLT-1 immunoreactivity was low. In contrast, GS immunoreactivity in plaques was subtle. These SP-rich regions seem to cause plaque-centric accumulation of astrocytic GLT-1 and AQP4, but not GS. Currently, we have no definite explanation for this phenomenon.
Perivascular astrocytes play a critical role in gliovascular coupling during excitatory synaptic activity [32, 36] . In AD, vascular amyloid may physically interfere with gliovascular signalling through altered GLT-1 and AQP4 expression. Although the expression of perivascular GLT-1 and AQP4 in our AD cases was not investigated in relation to vascular amyloid deposition, the loss of polarized GLT-1 and AQP4 expression on astrocyte end-feet along vessels suggests that alteration of the gliovascular and glymphatic pathways might contribute to Ab clearance.
Additionally, we observed a profound decrease in cortical astrocytic GS expression together with reduction in GLT-1 immunoreactivity in AD brains relative to controls. Several research groups have reported similar observations [37, 38] . In contrast, another study has demonstrated increased levels of GS immunoreactivity in the prefrontal cortex of the human AD brain; however, there was no description of AD pathological staging [39] . Moreover, a study using western blotting has revealed a decrease in astrocytic GS expression with preservation of GLT-1 expression in the brain of AD mice [40] . Although our data for GLT-1 and GS are not fully in accord with these earlier studies, the differences could be due to variations in AD pathological stage/lesion localization, species and the analytical methods employed. In any event, these reports also support the notion of dysfunction of the glutamate-glutamine cycle, and thus a role for glutamate-mediated neurotoxicity in the progression of AD.
In conclusion, progressive neurodegeneration in AD may occur in association with disruption of glutamate and water homoeostasis through altered astrocytic expression of GLT-1 and AQP4. Although activation of astrocytes may play a role in attenuating or exacerbating the pathology of AD [41, 42] , our present findings are insufficient to indicate the mechanisms involved. Also, as the number of cases we examined was relatively small, we may need to study a larger number of cases before we can draw definitive conclusions about the relationship between GLT-1 and AQP4. Further studies are needed to explore the mechanism of functional interaction between GLT-1 and AQP4 in the context of AD pathology, possibly leading to the development of a potential therapeutic avenue.
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